Insights

Israel’s HealthTech sector has long formed a central part of the nation’s technology ecosystem, establishing the country as a global hub for healthcare innovation. Despite private funding dropping to $455 million in the first half of this year – compared to the $712 million raised in the previous six months – 2024 is nevertheless shaping up to be a year of exceptional growth and investor confidence remains high.

Amidst the unprecedented challenges of the past 11 months, 2024 has been a pivotal year for Israel’s biotech sector, driven by strong global interest and AI-driven pharmaceutical advancements. Here we examine some of the key developments highlighting the resilience of Israel’s ecosystem and expectations for the remainder of the year.

Key Developments

CytoReason secured $80 million in funding to develop a computational model of the human body, streamlining the drug discovery process by enhancing the accuracy of human trials while reducing reliance on animal testing. CytoReason’s AI-driven platform and proprietary database are helping to accelerate decision-making for pharma and biotech firms, optimizing both the speed and cost-effectiveness of trial design.

Proscia announced its strategic partnership with Nucleai to revolutionize precision medicine by integrating Nucleai’s advanced spatial AI biomarker technology with Proscia’s Concentriq® enterprise pathology platform. Nucleai was also able to secure a $14 million investmentto expand deployment of its spatial biomarker technology, bringing the company’s total funding to date to $60 million.

In the first quarter of 2024, AION Labs launched two new companies. CombinAble.AI leverages AI and computational methods for biomolecule optimization simulations, reducing the time and cost of antibody discovery. TenAces integrates biology into its machine learning algorithms to enhance prediction capabilities in the development of new molecular glues for targeted protein degradation to treat a range of diseases.

QuantHealth received $2 million from Accenture Ventures to continue its work in AI-powered clinical trial simulation, bringing its total Series A funding to $17 million. QuantHealth’s AI platform utilizes an exhaustive dataset comprising 350 million patients, large biomedical knowledge graphs, and clinical trial data, to simulate and predict clinical trials results with 86% accuracy.

Founded in early 2024, Converge Bio is taking an ambitious approach to biological R&D with its generative AI platform for DNA, RNA, and protein sequencing. The startup aims to revolutionize the design and development of biological molecules harnessing the capabilities of Large Language Models (LLMs).

Biolojic Design entered into a $376 million multi-target drug discovery collaboration with Merck KGaA to develop AI-designed antibody-drug conjugates for oncology and immunology. The partnership is expected to result in multispecific antibodies to better target tumors while minimizing damage to healthy tissue.

Looking Ahead

As we look toward the rest of this year and beyond, Israel’s biotech sector is poised for continued growth, which will further establish the country as an emerging global hub for biotech innovation.

1. Increased governmental support will foster further advancements in computational biology and AI-powered innovation. The government has already committed to increase the Israel Innovation Authority’s budget to provide critical funding and new programs for the life sciences and healthcare industries.

2. Continued investor confidence will ensure a consistent flow of capital for Israeli startups and enterprises, with 59% of HealthTech VC funds remaining confident that the ongoing war will not impact 2024 investment decisions.

3. Growth through collaboration will remain central to Israel’s biotech success, combining domestic AI and computational expertise with global pharmaceutical experience. Such partnerships will continue driving innovation, improving precision to accelerate drug discovery and development.

4. New ventures will demonstrate the sector’s resilience, with new biotech enterprises continuing to emerge despite current challenges. Several projects are already underway with announcements expected that will encourage further confidence and growth.

Israel’s biotech industry is thus set to continue making a global impact. As we move through the remainder of 2024, the country is positioned to remain at the forefront of AI-powered innovation, driving new discoveries and opportunities for growth.

By Arnon Fluksman, PhD, Scientific Analyst, AION Labs